Vertex Pharmaceuticals price target raised to $525 from $456 at Leerink

Leerink raised the firm’s price target connected Vertex Pharmaceuticals (VRTX) to $525 from $456 and keeps an Outperform standing connected the shares. The steadfast cites an summation successful its terminal maturation presumption from 1% to 2%. Leerink is optimistic astir the company’s gross and pipeline prospects, which it expects to thrust banal terms performance. The steadfast would caveat that it projects higher concern spending maturation than statement models.

Claim 70% Off TipRanks This Holiday Season

• Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions

• Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected VRTX:

Disclaimer & DisclosureReport an Issue

• Vertex Pharmaceuticals: Strong Journavx Launch and Durable CF Franchise Underpin Buy Rating and Long-Term Growth Upside

• Vertex Pharmaceuticals: Strong Market Position and Promising Growth Potential Justify Buy Rating

• Vertex Pharmaceuticals: Promising Advancements successful Kidney Disease Treatments Drive Buy Rating

• Vertex Pharmaceuticals presents caller information connected CASGEVY astatine ASH

• Vertex Pharmaceuticals terms people raised to $564 from $516 astatine Morgan Stanley